Exposure to pesticides raises myeloma risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

People who apply certain pesticides double their chance of developing multiple myeloma, compared with individuals in the general population.

People who apply certain pesticides double their chance of developing multiple myeloma, compared with individuals in the general population. Data culled from a U.S. Agricultural Health Study found higher rates of monoclonal gammopathy of undetermined significance in 678 individuals who applied certain pesticides, compared with a control population. MGUS is a precancerous condition that can lead to multiple myeloma (Blood 113:6386-6391, 2009).

The participants (median age 60) were farmers in Iowa and North Carolina who were licensed to apply restricted-use pesticides. The researchers found a significantly increased risk of MGUS among users of dieldrin (5.6-fold increase in risk), carbon-tetrachloride/carbon disulfide (3.9-fold increase in risk), and chlorothalonil (2.4-fold increase in risk).

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Related Content